About Us
Green Park & Golf, built on over 60 years of operational and financial experience, seeks investment opportunities that offer above-market returns for its investors. Led by Clay Heighten, M.D., and Carl Soderstrom, the Firm delivers strategic solutions, financial backing and a reliable network to its portfolio companies. The Dallas-based Firm is currently looking for investment opportunities in medical-related start-ups.
Investment Strategy
Green Park & Golf’s strategy is grounded in the successful methodologies that Dr. Heighten and Mr. Soderstrom used in building MedicalEdge and PhyServe. We are looking for:
Companies that treat others with compassion, dignity and respect
Fresh ideas, and ones that can be “disruptive” to the norms in their market space
Passionate, seasoned, and energetic management teams of two or more
Large market opportunities with high barriers to entry
Alignment of incentives across the owners, management, and employees
Green Park & Golf enjoys superior deal flow as a result of our past experiences and vast network that has been built on a successful operating and investment history. Our typical investment ranges from $100,000 to $1,000,000 and is used for either start-up or growth capital. Our activity in the investment depends on the needs of the entrepreneur and life stage of the company.
Our Team
Carl Soderstrom
Mr. Soderstrom is a founding partner of Green Park & Golf Ventures, an early stage venture capital investment company. He is a member of the board of directors of... Read More
Dr. Clay Heighten
Dr. Heighten is a founding member of Green Park and Golf Ventures. After completion of residency training at the Southwestern Medical School affiliated Parkland... Read More
JR Garcia
Mr. Garcia joined Green Park & Golf Ventures as the first employee and has been instrumental in the evolution of the firm since the first investment. Read More
Dr. Lauren Tyra
Dr. Tyra joined Green Park & Golf in 2017 as an Analyst. Prior to joining Green Park & Golf, she completed graduate studies in the Neuroscience... Read More
Daniel S. Parsley
Daniel is the Managing Partner of GPG Ventures - Houston. Daniel is a native of Houstonian where he has been an active venture investor in early stage medical device, biotech… Read More
John Leader
John joined GPG Ventures – Houston as a Principal in charge of Investment Operations in May of 2019. John oversees the deal pipeline and evaluation of potential… Read More
Claire England
Claire joined GPG Ventures in 2023 and serves as Investment Partner. She's building the firm's new Austin presence, helping GPG become the first VC firm with offices in three major Texas cities… Read More
News / Press Releases
Noninvasix announced today that its LIVOx™ Central Venous Oxygenation Monitor has received Breakthrough Device Designation from the U.S. Food and Drug Administration
Noninvasix will be the first company to non-invasively monitor sepsis by detecting the key indicator of septic shock as early as possible so it can be treated to reduce complications and save lives. The LIVOx Central Venous Oxygenation Monitor can provide for a more effective diagnosis of this life-threatening condition.
With $20M Cash Infusion, Genomenon Seeks to Curate Entire Human Genome
Following the closing of a $20 million Series B funding round […] Genomenon plans to advance its goal of curating the entire human genome through its artificial intelligence-based Mastermind Genomic Search Engine.
Blackstone Growth (BXG) Announces Majority Investment in Supergoop!
Blackstone (NYSE:BX) today announced that funds managed by Blackstone Growth (BXG) (“Blackstone”) have entered into a definitive agreement for a majority investment in Supergoop!, the first protective skincare brand that puts SPF at the forefront
(MICROTRANSPONDER) - FDA Approves First-of-Its-Kind Stroke Rehabilitation System
The U.S. Food and Drug Administration today approved the MicroTransponder Vivistim Paired VNS System. The Vivistim System was granted Breakthrough Device designation. The FDA reviewed the MicroTransponder Vivistim Paired VNS System under the Premarket Approval (PMA) pathway
LTK(rewardstyle) Announces SoftBank Vision Fund 2 Investment
A $300 million investment by SoftBank Vision Fund 2 will supercharge talent and product development across LTK’s creator, brand and consumer shopping experiences
Recuro Health Receives Investment by DeepWork Capital and GPG Ventures
Proceeds to Accelerate Growth, Marketing and Expanded Capabilities in Digital Health. Recuro Health is proud to announce that the company has received additional investment through its partnerships with DeepWork Capital and GPG Ventures, bringing total raised capital to $22 million
“I was impressed with how quickly GPG Ventures grasped my business model and led our raise. Within a relatively short time they committed to lead the round and had it oversubscribed with a raise over $2M.”
Russell Moon, CEO of PerioSciences
OUR STORY
Green Park & Golf, built on over 60 years of operational and financial experience, seeks investment opportunities that offer above-market returns for its investors. Led by Clay Heighten, M.D., and Carl Soderstrom, the Firm delivers strategic solutions, financial backing and a reliable network to its portfolio companies. The Dallas-based Firm is currently looking for investment opportunities in medical-related start-ups.
Dr. Heighten founded MedicalEdge Healthcare Group in 1993, and Mr. Soderstrom started PhyServe Physician Services in 1998 to administer the financial and operational needs of MedicalEdge. Together, the companies managed over 550 providers in five major markets. In 2011, the companies were sold to Texas Health Resources, a $3.8 billion health care system. That’s when Green Park & Golf was born.
After earning his MBA at Southern Methodist University, Mr. Garcia joined them full-time in May 2011 to actively pursue new investment opportunities and monitor other investments in their portfolio. He has prior professional experience at FedEx, Bold Ventures, and Lone Star Investment Advisors.
